Astellas Pharma IncEigentümerstruktur
| Preis (2026-07-30) | 52W Hoch | 52W Tief |
| 14.42 USD | 16,769 USD | 10,058 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| - USD | - | - | - | - | - |
| #Shares | Short [%] | Short Ratio |
| 1.791.492.258 | - | - |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Astellas Pharma Inc
Mitarbeiter 14.099
Handelsplatz PINK
Ticker Symbol ALPMY
IPO Datum -
Adresse 2-5-1, Nihonbashi-Honcho, Chuo, Japan, 103-8411
Webseite https://www.astellas.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. Naoki Okamura BSc | President, CEO & Representative Director |
| 2 | Mr. Katsuyoshi Sugita | Executive VP, Chief People Officer & Representative Director |
| 3 | Mr. Atsushi Kitamura | Chief Financial Officer |
| 4 | Nobue Yasuda | General Manager of Finance & Accounting Department |
| 5 | Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer |
| 6 | Ms. Nobuko Kato | Chief Communications & Investor Relations Officer |
| 7 | Ms. Tatjana Dragovic J.D. | General Counsel, Chief Ethics & Compliance Officer |
| 8 | Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive |
| 9 | Mr. Jun Kono M.B.A. | Senior Executive Officer & Head of Japan Commercial |
| 10 | Ms. Leticia Delgado-Herrera | VP and Rx+ M&D Head |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
Für dieses Unternehmen liegen derzeit keine Daten zu institutionellen Investoren vor.